Zevra Therapeutics, Inc.ZVRANASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +27.63% | -8.88% | +495.65% | +481.73% | +605.36% |
| Gross Profit Growth | -49.40% | +2.36% | +11810.00% | +1441.32% | +1660.78% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +37.68% | +41.61% | +29.48% | +30.74% | +17.03% |
| Weighted Average Shares Diluted Growth | +37.68% | +41.61% | +29.48% | +34.43% | +17.03% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -21.53% | -39.52% | +51.92% | +104.16% | +116.19% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +37.82% | +3.37% | +14.16% | +77.47% | +41.02% |
| Book Value per Share Growth | -24.89% | -54.72% | -35.10% | +176.07% | +63.09% |
| Debt Growth | +33.69% | +37.77% | +39.63% | +4.72% | +4.66% |
| R&D Expense Growth | -10.99% | -5.08% | -69.59% | -67.37% | -68.64% |
| SG&A Expenses Growth | +178.58% | +10.02% | +96.81% | +64.88% | +4.49% |